Trovafloxacin

Trovafloxacin is a broad-spectrum fluoroquinolone antibiotic that was introduced in the late 1990s for the treatment of a wide range of bacterial infections. It is a synthetic antibiotic that inhibits the bacterial enzyme DNA gyrase, preventing DNA replication and thus bacterial cell division. Trovafloxacin was designed to have enhanced activity against Gram-positive bacteria while retaining the activity of other fluoroquinolones against Gram-negative bacteria. Its broad spectrum of activity included efficacy against pathogens responsible for community-acquired pneumonia, complicated intra-abdominal infections, and certain sexually transmitted infections.

Medical Uses

Trovafloxacin was used to treat various bacterial infections including pneumonia, skin infections, pelvic inflammatory disease, and infections of the urinary tract, among others. It was particularly noted for its effectiveness against difficult-to-treat infections caused by resistant strains of bacteria.

Adverse Effects

Despite its initial promise, the use of trovafloxacin was associated with serious adverse effects. The most concerning was its potential to cause liver toxicity, including cases of acute liver failure. Other reported side effects included gastrointestinal disturbances, skin reactions, and central nervous system effects such as dizziness and confusion.

Regulatory Actions

Due to the risk of severe hepatotoxicity, the use of trovafloxacin was severely restricted. In the United States, the Food and Drug Administration (FDA) issued a Black Box Warning, the agency's strongest warning, and its use was limited to patients with serious infections for whom no alternative treatments were available. Eventually, trovafloxacin was withdrawn from the market in many countries, including the United States.

Mechanism of Action

Trovafloxacin acts by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. DNA gyrase is involved in the supercoiling of bacterial DNA, which is necessary for DNA replication and transcription. Topoisomerase IV is involved in the separation of replicated bacterial DNA. By inhibiting these enzymes, trovafloxacin prevents bacterial DNA replication, transcription, and cell division, leading to the death of the bacterial cell.

Pharmacokinetics

Trovafloxacin is well absorbed from the gastrointestinal tract, with bioavailability exceeding 90%. It is metabolized in the liver and excreted primarily in the bile and feces. The drug has a relatively long half-life, allowing for once-daily dosing.

Controversies and Legal Issues

The introduction of trovafloxacin was followed by reports of severe liver injury, including fatalities. This led to numerous lawsuits against the manufacturer, alleging failure to adequately warn about the drug's risks. The controversy surrounding trovafloxacin highlighted the importance of post-marketing surveillance in identifying rare but serious adverse drug reactions.

Conclusion

While trovafloxacin was initially hailed as a significant advancement in antibiotic therapy, its potential for causing severe liver damage led to its downfall. The trovafloxacin case underscores the challenges in balancing the benefits of new antibiotics against their risks, especially when those risks are rare but severe.

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian